• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[缺血性中风治疗中得到证实的内容]

[What is confirmed in the treatment of ischemic stroke].

作者信息

Worthmann Hans, Ernst Johanna, Grosse Gerrit M

机构信息

Neurologische Klinik mit Klinischer Neurophysiologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30623, Hannover, Deutschland.

出版信息

Inn Med (Heidelb). 2023 Dec;64(12):1143-1153. doi: 10.1007/s00108-023-01622-x. Epub 2023 Nov 10.

DOI:10.1007/s00108-023-01622-x
PMID:37947809
Abstract

Ischemic stroke is one of the leading causes of death worldwide and the most frequent cause of permanent disability in adulthood. The acute treatment of stroke is time-critical and, according to the time is brain principle, it is important to determine as soon as possible whether recanalization treatment that can save the penumbra is possible. Intravenous thrombolysis (IVT) and, if a large vessel occlusion is identified, endovascular treatment (EVT) possibly in combination with IVT, are recommended. Further treatment in a stroke unit is another important component of acute stroke treatment. The best secondary preventive treatment must already be initiated in the acute phase. The cause of stroke guides making decisions on the ideal secondary preventive strategy. The most important etiologies of stroke are cardiac embolism, atherosclerotic macroangiopathy and cerebral microangiopathy (small vessel disease). Less frequent causes are dissections of arteries supplying the brain or vasculitis. In up to 20-30% of all cases, however, no clear etiology can be determined despite intensive investigation of the cause. This means corresponding uncertainty in the optimal secondary prevention that consists in particular of an anticoagulant medication adapted to the etiology, treatment of cardiovascular risk factors and if necessary surgical or interventional desobliterative procedures. This article describes the diagnostic procedure and the evidence-based treatment of ischemic stroke.

摘要

缺血性中风是全球主要死因之一,也是成年人永久性残疾的最常见原因。中风的急性治疗对时间要求极为关键,根据“时间就是大脑”的原则,尽快确定是否有可能进行挽救半暗带的再通治疗非常重要。推荐进行静脉溶栓(IVT),如果发现大血管闭塞,则可能需要进行血管内治疗(EVT),也可能联合IVT。在卒中单元进行进一步治疗是急性中风治疗的另一个重要组成部分。最佳的二级预防治疗必须在急性期就开始。中风的病因指导着理想二级预防策略的决策。中风最重要的病因是心脏栓塞、动脉粥样硬化性大血管病变和脑微血管病变(小血管疾病)。较少见的病因是供应脑部的动脉夹层或血管炎。然而,在所有病例中,高达20%-30%的患者尽管对病因进行了深入调查,仍无法确定明确的病因。这意味着在最佳二级预防方面存在相应的不确定性,二级预防尤其包括根据病因调整的抗凝药物治疗、心血管危险因素的治疗以及必要时的手术或介入性血管再通手术。本文描述了缺血性中风的诊断程序和循证治疗。

相似文献

1
[What is confirmed in the treatment of ischemic stroke].[缺血性中风治疗中得到证实的内容]
Inn Med (Heidelb). 2023 Dec;64(12):1143-1153. doi: 10.1007/s00108-023-01622-x. Epub 2023 Nov 10.
2
Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.急性缺血性脑卒中动脉内脑溶栓的试验设计与报告标准。
Stroke. 2003 Aug;34(8):e109-37. doi: 10.1161/01.STR.0000082721.62796.09. Epub 2003 Jul 17.
3
Endovascular therapy with or without intravenous thrombolysis in acute stroke with tandem occlusion.急性串联性闭塞卒中血管内治疗联合或不联合静脉溶栓治疗。
J Neurointerv Surg. 2022 Apr;14(4):314-320. doi: 10.1136/neurintsurg-2020-017202. Epub 2021 Apr 28.
4
Endovascular Treatment With or Without Prior Intravenous Alteplase for Acute Ischemic Stroke.血管内治疗伴或不伴静脉内阿替普酶治疗急性缺血性脑卒中。
J Am Heart Assoc. 2019 Jun 4;8(11):e011592. doi: 10.1161/JAHA.118.011592. Epub 2019 May 29.
5
Endovascular thrombectomy or bridging therapy in minor ischemic stroke with large vessel occlusion.血管内血栓切除术或桥接治疗小面积缺血性卒中伴大血管闭塞。
Thromb Res. 2022 Nov;219:150-154. doi: 10.1016/j.thromres.2022.09.020. Epub 2022 Sep 25.
6
Bridging versus Direct Mechanical Thrombectomy in Acute Ischemic Stroke: A Subgroup Pooled Meta-Analysis for Time of Intervention, Eligibility, and Study Design.桥接与直接机械取栓治疗急性缺血性脑卒中的比较:基于干预时间、入选标准和研究设计的亚组汇总荟萃分析。
Cerebrovasc Dis. 2020;49(2):223-232. doi: 10.1159/000507844. Epub 2020 Apr 24.
7
Treatments in Ischemic Stroke: Current and Future.缺血性脑卒中的治疗:现状与未来。
Eur Neurol. 2022;85(5):349-366. doi: 10.1159/000525822. Epub 2022 Aug 2.
8
Endovascular treatment and cognitive outcome after anterior circulation ischemic stroke.血管内治疗与前循环缺血性脑卒中后的认知结局。
Sci Rep. 2020 Oct 28;10(1):18524. doi: 10.1038/s41598-020-75609-1.
9
Intravenous thrombolysis + endovascular thrombectomy versus thrombolysis alone in large vessel occlusion mild stroke: a propensity score matched analysis.静脉溶栓联合血管内取栓与单纯溶栓治疗大血管闭塞性轻度卒中的倾向评分匹配分析
Eur J Neurol. 2023 May;30(5):1312-1319. doi: 10.1111/ene.15722. Epub 2023 Feb 24.
10
Update of Intravenous Thrombolytic Therapy in Acute Ischemic Stroke.急性缺血性脑卒中的静脉溶栓治疗更新。
Acta Neurol Taiwan. 2021 Jun 30;30(2):44-53.

本文引用的文献

1
Diagnostic value of carotid intima-media thickness and clinical risk scores in determining etiology of ischemic stroke.颈动脉内膜中层厚度和临床风险评分对确定缺血性脑卒中病因的诊断价值。
Eur Stroke J. 2023 Sep;8(3):738-746. doi: 10.1177/23969873231182492. Epub 2023 Jun 19.
2
Early or late initiation of dabigatran versus vitamin-K-antagonists in acute ischemic stroke or TIA: The PRODAST study.达比加群酯与维生素 K 拮抗剂治疗急性缺血性卒中和 TIA 的早期或晚期启动:PRODAST 研究。
Int J Stroke. 2023 Dec;18(10):1169-1177. doi: 10.1177/17474930231184366. Epub 2023 Jul 4.
3
Early versus Later Anticoagulation for Stroke with Atrial Fibrillation.
早期与晚期抗凝治疗房颤相关性脑卒中。
N Engl J Med. 2023 Jun 29;388(26):2411-2421. doi: 10.1056/NEJMoa2303048. Epub 2023 May 24.
4
Trial of Thrombectomy 6 to 24 Hours after Stroke Due to Basilar-Artery Occlusion.基底动脉闭塞性卒中发病 6 至 24 小时内取栓治疗的试验
N Engl J Med. 2022 Oct 13;387(15):1373-1384. doi: 10.1056/NEJMoa2207576.
5
Trial of Endovascular Treatment of Acute Basilar-Artery Occlusion.急性基底动脉闭塞血管内治疗试验。
N Engl J Med. 2022 Oct 13;387(15):1361-1372. doi: 10.1056/NEJMoa2206317.
6
Dual vs. mono antiplatelet therapy for acute ischemic stroke or transient ischemic attack with evidence of large artery atherosclerosis.针对伴有大动脉粥样硬化证据的急性缺血性卒中或短暂性脑缺血发作,双重抗血小板治疗与单一抗血小板治疗的比较
Front Neurol. 2022 Sep 12;13:923142. doi: 10.3389/fneur.2022.923142. eCollection 2022.
7
Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study.急性缺血性卒中和心房颤动(TIMING)后早期与延迟非维生素 K 拮抗剂口服抗凝治疗:一项基于登记的随机对照非劣效性研究。
Circulation. 2022 Oct 4;146(14):1056-1066. doi: 10.1161/CIRCULATIONAHA.122.060666. Epub 2022 Sep 6.
8
Review and update of the concept of embolic stroke of undetermined source.不明来源栓塞性卒中概念的回顾与更新。
Nat Rev Neurol. 2022 Aug;18(8):455-465. doi: 10.1038/s41582-022-00663-4. Epub 2022 May 10.
9
Rationale, Design and Methods of the Prospective Record of the Use of Dabigatran in Patients with Acute Stroke or TIA (PRODAST) Study.达比加群在急性卒中或短暂性脑缺血发作患者中应用的前瞻性记录(PRODAST)研究的原理、设计与方法
Eur Stroke J. 2021 Dec;6(4):438-444. doi: 10.1177/23969873211060219. Epub 2021 Nov 17.
10
European Stroke Organisation - European Society for Minimally Invasive Neurological Therapy expedited recommendation on indication for intravenous thrombolysis before mechanical thrombectomy in patients with acute ischaemic stroke and anterior circulation large vessel occlusion.欧洲卒中组织-欧洲微创神经治疗学会关于急性缺血性卒中合并前循环大血管闭塞患者在机械取栓术前静脉溶栓指征的快速推荐意见
Eur Stroke J. 2022 Mar;7(1):I-XXVI. doi: 10.1177/23969873221076968. Epub 2022 Feb 17.